Comments
Loading...

Stem Cell Authority Analyst Ratings

SCALOTCEM
Logo brought to you by Benzinga Data
$0.00450
At close: Dec 31, 10:01 AM EDT

Stem Cell Authority Analyst Ratings and Price Targets | OTC:SCAL | Benzinga

Stem Cell Authority Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Stem Cell Authority Corp from these most-recent analyst ratings.

Analyst Ratings for Stem Cell Authority

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Stem Cell Authority (SCAL) stock?

A

There is no price target for Stem Cell Authority

Q

What is the most recent analyst rating for Stem Cell Authority (SCAL)?

A

There is no analyst for Stem Cell Authority

Q

When was the last upgrade for Stem Cell Authority (SCAL)?

A

There is no last upgrade for Stem Cell Authority

Q

When was the last downgrade for Stem Cell Authority (SCAL)?

A

There is no last downgrade for Stem Cell Authority.

Q

When is the next analyst rating going to be posted or updated for Stem Cell Authority (SCAL)?

A

There is no next analyst rating for Stem Cell Authority.

Q

Is the Analyst Rating Stem Cell Authority (SCAL) correct?

A

There is no next analyst rating for Stem Cell Authority.

Browse analyst ratings and price targets on all stocks.